טוען...
4CPS-159 Quality of life assessment and efficacy of secukinumab in plaque psoriasis disease
BACKGROUND: Secukinumab has demonstrated efficacy in moderate to severe plaque psoriasis (PP) by improving the Psoriasis Area and Severity Index (PASI), but patients’ quality of life is not always quantified in clinical trials. PURPOSE: To evaluate the efficacy of secukinumab in PP treatment and how...
שמור ב:
| הוצא לאור ב: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMJ Group
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535509/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.250 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|